September 14, 2022 MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission Read press release
September 13, 2022 MedinCell releases the results of its September 8, 2022 ordinary annual and extraordinary general meeting Read press release
September 5, 2022 MedinCell secures additional 20 million euros financing with the European Investment Bank (EIB) Read press release
August 29, 2022 Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology Read press release
August 17, 2022 An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report Read press release